Literature DB >> 29899105

Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.

Juntao Shen1, Jinjie Zhou1, Guo-Qiang Chen2, Zhi-Long Xiu3.   

Abstract

Klebsiella pneumoniae is one of the most common nosocomial opportunistic pathogens and usually exhibits multiple-drug resistance. Phage therapy, a potential therapeutic to replace or supplement antibiotics, has attracted much attention. However, very few Klebsiella phages have been well characterized because of the lack of efficient genome-editing tools. Here, Cas9 from Streptococcus pyogenes and a single guide RNA (sgRNA) were used to modify a virulent Klebsiella bacteriophage, phiKpS2. We first evaluated the distribution of sgRNA activity in phages and proved that it is largely inconsistent with the predicted activity from current models trained on eukaryotic cell data sets. A simple CRISPR-based phage genome-editing procedure was developed based on the discovery that homologous arms as short as 30 to 60 bp were sufficient to introduce point mutation, gene deletion, and swap. We also demonstrated that weak sgRNAs could be used for precise phage genome editing but failed to select random recombinants, possibly because inefficient cleavage can be tolerated through continuous repair by homologous recombination with the uncut genomes. Small frameshift deletion was proved to be an efficient way to evaluate the essentiality of phage genes. By using the abovementioned strategies, a putative promoter and nine genes of phiKpS2 were successfully deleted. Interestingly, the holin gene can be deleted with little effect on phiKpS2 infection, but the reason is not yet clear. This study established an efficient, time-saving, and cost-effective procedure for phage genome editing, which is expected to significantly promote the development of bacteriophage therapy.IMPORTANCE In the present study, we have addressed efficient, time-saving, and cost-effective CRISPR-based phage genome editing of Klebsiella phage, which has the potential to significantly expand our knowledge of phage-host interactions and to promote applications of phage therapy. The distribution of sgRNA activity was first evaluated in phages. Short homologous arms were proven to be enough to introduce point mutation, small frameshift deletion, gene deletion, and swap into phages, and weak sgRNAs were proven useful for precise phage genome editing but failed to select random recombinants, all of which makes the CRISPR-based phage genome-editing method easier to use.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CRISPR-Cas9; DNA double-strand break repair; genome editing; sgRNA activity; short homologous arms; virulent Klebsiella phage

Mesh:

Substances:

Year:  2018        PMID: 29899105      PMCID: PMC6096830          DOI: 10.1128/JVI.00534-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  DNA primase acts as a molecular brake in DNA replication.

Authors:  Jong-Bong Lee; Richard K Hite; Samir M Hamdan; X Sunney Xie; Charles C Richardson; Antoine M van Oijen
Journal:  Nature       Date:  2006-02-02       Impact factor: 49.962

2.  Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella pneumoniae: implication in typing and treatment.

Authors:  Tzu-Lung Lin; Pei-Fang Hsieh; Yu-Tsung Huang; Wei-Ching Lee; Yi-Ting Tsai; Po-An Su; Yi-Jiun Pan; Chun-Ru Hsu; Meng-Chuan Wu; Jin-Town Wang
Journal:  J Infect Dis       Date:  2014-07-07       Impact factor: 5.226

3.  Uncovering Earth's virome.

Authors:  David Paez-Espino; Emiley A Eloe-Fadrosh; Georgios A Pavlopoulos; Alex D Thomas; Marcel Huntemann; Natalia Mikhailova; Edward Rubin; Natalia N Ivanova; Nikos C Kyrpides
Journal:  Nature       Date:  2016-08-17       Impact factor: 49.962

4.  Internal proteins of bacteriophage T7.

Authors:  P Serwer
Journal:  J Mol Biol       Date:  1976-11-05       Impact factor: 5.469

5.  Improved sgRNA design in bacteria via genome-wide activity profiling.

Authors:  Jiahui Guo; Tianmin Wang; Changge Guan; Bing Liu; Cheng Luo; Zhen Xie; Chong Zhang; Xin-Hui Xing
Journal:  Nucleic Acids Res       Date:  2018-08-21       Impact factor: 16.971

6.  Phage response to CRISPR-encoded resistance in Streptococcus thermophilus.

Authors:  Hélène Deveau; Rodolphe Barrangou; Josiane E Garneau; Jessica Labonté; Christophe Fremaux; Patrick Boyaval; Dennis A Romero; Philippe Horvath; Sylvain Moineau
Journal:  J Bacteriol       Date:  2007-12-07       Impact factor: 3.490

7.  Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system.

Authors:  Ruth Kiro; Dror Shitrit; Udi Qimron
Journal:  RNA Biol       Date:  2014-01-22       Impact factor: 4.652

8.  Bacteriophage DNA glucosylation impairs target DNA binding by type I and II but not by type V CRISPR-Cas effector complexes.

Authors:  Marnix Vlot; Joep Houkes; Silke J A Lochs; Daan C Swarts; Peiyuan Zheng; Tim Kunne; Prarthana Mohanraju; Carolin Anders; Martin Jinek; John van der Oost; Mark J Dickman; Stan J J Brouns
Journal:  Nucleic Acids Res       Date:  2018-01-25       Impact factor: 16.971

9.  RNA-guided editing of bacterial genomes using CRISPR-Cas systems.

Authors:  Wenyan Jiang; David Bikard; David Cox; Feng Zhang; Luciano A Marraffini
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

10.  Consequences of Cas9 cleavage in the chromosome of Escherichia coli.

Authors:  Lun Cui; David Bikard
Journal:  Nucleic Acids Res       Date:  2016-04-08       Impact factor: 16.971

View more
  10 in total

1.  Harnessing stepping-stone hosts to engineer, select, and reboot synthetic bacteriophages in one pot.

Authors:  Li Cheng; Ziqing Deng; Haoran Tao; Wenchen Song; Bo Xing; Wenfeng Liu; Lingxin Kong; Shengjian Yuan; Yingfei Ma; Yayun Wu; Xun Huang; Yun Peng; Nai-Kei Wong; Yingxia Liu; Yun Wang; Yue Shen; Junhua Li; Minfeng Xiao
Journal:  Cell Rep Methods       Date:  2022-05-23

Review 2.  Genetic Engineering of Bacteriophages Against Infectious Diseases.

Authors:  Yibao Chen; Himanshu Batra; Junhua Dong; Cen Chen; Venigalla B Rao; Pan Tao
Journal:  Front Microbiol       Date:  2019-05-03       Impact factor: 5.640

3.  Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.

Authors:  Małgorzata Łobocka; Krystyna Dąbrowska; Andrzej Górski
Journal:  BioDrugs       Date:  2021-04-21       Impact factor: 5.807

Review 4.  A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens.

Authors:  Vivek K Mutalik; Adam P Arkin
Journal:  iScience       Date:  2022-03-19

5.  CRISPR-Cas9 Based Bacteriophage Genome Editing.

Authors:  Xueli Zhang; Chaohui Zhang; Caijiao Liang; Bizhou Li; Fanmei Meng; Yuncan Ai
Journal:  Microbiol Spectr       Date:  2022-07-26

Review 6.  Bacteriophages of Klebsiella spp., their diversity and potential therapeutic uses.

Authors:  Warren P Herridge; Preetha Shibu; Jessica O'Shea; Thomas C Brook; Lesley Hoyles
Journal:  J Med Microbiol       Date:  2020-01-24       Impact factor: 2.472

Review 7.  CRISPR-Cas9/Cas12a biotechnology and application in bacteria.

Authors:  Ruilian Yao; Di Liu; Xiao Jia; Yuan Zheng; Wei Liu; Yi Xiao
Journal:  Synth Syst Biotechnol       Date:  2018-10-03

8.  Comparison of CRISPR and Marker-Based Methods for the Engineering of Phage T7.

Authors:  Aurelija M Grigonyte; Christian Harrison; Paul R MacDonald; Ariadna Montero-Blay; Matthew Tridgett; John Duncan; Antonia P Sagona; Chrystala Constantinidou; Alfonso Jaramillo; Andrew Millard
Journal:  Viruses       Date:  2020-02-10       Impact factor: 5.818

9.  Optimization of T4 phage engineering via CRISPR/Cas9.

Authors:  Michelle M Duong; Caitlin M Carmody; Qinqin Ma; Joseph E Peters; Sam R Nugen
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

10.  Distribution of CRISPR Types in Fluoroquinolone-Resistant Campylobacter jejuni Isolates.

Authors:  Mehmet Cemal Adiguzel; Debora Brito Goulart; Zuowei Wu; Jinji Pang; Seyda Cengiz; Qijing Zhang; Orhan Sahin
Journal:  Pathogens       Date:  2021-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.